Corpus ID: 24111474

Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.

@article{Davis1978PharmacologicalIO,
  title={Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.},
  author={Kenneth L. Davis and Philip A. Berger},
  journal={Biological psychiatry},
  year={1978},
  volume={13 1},
  pages={
          23-49
        }
}
The hypotheses of relative cholinergic underactivity in Huntington's disease, tardive dyskinesia, mania, and schizophrenia were pharmacologically investigated, using physostigmine and choline chloride. Intravenous physostigmine improved the involuntary movements of all of four patients with tardive dyskinesia and three of six patients with Huntington's disease. Physostigmine infusion also decreased manic symptoms in six of nine patients with mania, but had no beneficial effects in three… Expand
The Cholinergic System in Schizophrenia Reconsidered: Anticholinergic Modulation of Sleep and Symptom Profiles
The role of the cholinergic system in schizophrenia remains controversial. A series of investigations are reviewed that describe the effects of pharmacological manipulation of the cholinergic systemExpand
Do Acetylcholinesterase Inhibitors Have a Role in Improving Cognitive Impairment in Patients with Schizophrenia?
TLDR
Acetylcholinesterase inhibitors (AChEIs) that have been proven to be effective on psychiatric symptoms, behavioural abnormalities and cognitive dysfunction of patients with dementia may beeffective on cognitive deficit in patients with schizophrenia, and may also improve their psychopathology and behaviour. Expand
Adverse effects of anticholinergic medication on positive schizophrenic symptoms.
TLDR
The findings support earlier claims that anticholinergic medication has adverse effects on schizophrenic symptoms and support the idea that patients resistant to the effects of neuroleptic medication are likely to be given the highest doses. Expand
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
TLDR
This review provides no strong evidence for the use of cholinergic agents in the treatment of neuroleptic-induced tardive dyskinesia and, because of the small sample size, the cumulative data must be interpreted as inconclusive. Expand
Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents
  • T. Burt
  • Psychology, Medicine
  • Current psychiatry reports
  • 2000
TLDR
Preliminary observations suggest the possible value of ChEIs in the management of behavioral dysregulation, apathy, irritability, psychosis, depression, mania, tics, and delirium and in the diagnosis of depression, panic, and personality disorders. Expand
Acetylcholine and affective disorder
TLDR
Although the proposal that affective disorders involve cholinergic neurons has received some support from clinical investigation further research is required to substantiate the intriguing observations to date and to clarify the physiologic and psychologic processes mediating them. Expand
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice.
Cholinesterase inhibitors are commonly used to improve cognition and treat psychosis and other behavioral symptoms in Alzheimer's disease, Parkinson's disease, and other neuropsychiatric conditions.Expand
Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
TLDR
Whether the use or the withdrawal of anticholinergic drugs are clinically effective for the treatment of people with both antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illness is investigated. Expand
Pharmacology of Central Cholinergic Mechanisms and Schizophrenic Disorders
TLDR
The advent of neuroleptics as antipsychotic agents and the elegant methodology available for the neuroanatomical, neurochemical, neurophysiological and neuropharmacological study of the catecholaminergic pathways have promoted scientific attention on the possible role these brain systems may play in the pathophysiology of schizophrenia. Expand
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
TLDR
It is possible that nicotinic receptor desensitization produced by chronic tobacco use in schizophrenic patients rendered their Nicotinic receptors refractory to the effects of increased agonist activity produced by donepezil. Expand
...
1
2
3
4
5
...